Novartis (NVS.US) has received approval from the European Commission for its important small molecule drug, which is expected to transform the treatment of early-stage breast cancer.

Novartis will continue to evaluate the long-term outcomes of NATALEE patients, including overall survival.

Zhitong FinanceNov 27 18:43 ET

European Commission Approves Products by BeiGene, GSK and Novartis

Seeking AlphaNov 27 08:41 ET

The European Commission Has Approved Novartis' Kisqali (Ribociclib) In Combination With An Aromatase Inhibitor For The Adjuvant Treatment Of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer At High Risk...

BenzingaNov 27 05:09 ET

Novartis' Early Breast Cancer Drug Gets Approval From EU Commission

MT NewswiresNov 27 01:41 ET

Octavian AG Lifts Price Target on Novartis, Maintains Hold Recommendation

MT NewswiresNov 26 09:30 ET · Ratings

Novartis (NVS.US) has launched hydrochloride acyclovir tablets in the domestic market, indicated for IgA nephropathy.

Acarbose is an investigational high-potency selective oral ETA (endothelin A) receptor antagonist, activation of the ETA receptor results in increased proteinuria, which is associated with kidney damage, fibrosis, and loss of renal function in IgA nephropathy.

Zhitong FinanceNov 25 20:32 ET